Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

Perspectives from John J. Oppenheimer, MD; Sarah Rhoads, MD Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

In her budget speech, Finance Minister Nirmala Sitharaman announced the exemption of 36 drugs used to treat cancer, rare ...

Cancer patients to receive relief on imported medicines through Basic Customs Duty exemptions and patient assistance ...

The National Pharmaceutical Pricing Authority directs pharma firms to revise the MRP of medicines following customs duty ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Asthma a chronic respiratory condition may be driven by specific immune cells that influence inflammation and severity ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of the budget announcements.